contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-health-market-opening-will-soon-be-tested

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

A couple of months ago, I pondered that the company’s board is very homegrown for a global growth phase, and indeed, so is the management team. Finally, we are starting to build what is needed for the international growth phase, but the execution is very cautious, and at least a year late. As I already wrote in the options chain, I prefer leadership that boldly builds the future a bit ahead of time, not belatedly. Well, better now than never, but at least a couple of new people also on the board, and more people who have already earned their stripes in the management team!

Damn it. I have a hunch that Barrett is leaving on his own initiative. He is the only person in the company’s management team who has managed to communicate the importance of technology in a way that others besides geeks understand, and Suna has not shown any signs of learning. As a reminder of Barrett’s communication skills, here’s the May webinar I commented on at the time:  \u003e Jeffrey Barrett’s description of the scientific basis of the analysis (starting at 17m30s) is the best description of Nightingale’s differentiation I’ve heard so far - especially better than the CEO’s high-level fluff. Similarly, Charles Alessi’s (starting at 33m) example of data usage in a clinical context is excellently practical. To my knowledge, Nightingale has not communicated things like this before. CEO Suna, on the other hand, has been rambling about the same things for at least seven years, since I first heard him. Those talks haven’t significantly built credibility. https://youtu.be/mb64f6iEMqE I wouldn’t be worried about the continuation of scientific development; they’ve been able to develop science until now. But where are product development, commercial development, and SALES development? Just over a year ago, I considered this a fairly risk-free stock in my portfolio, especially compared to my previous position, but since then, a third of the capital has melted away while the rest of the market has risen by a third. It wasn’t risk-free, and with these steps, the risks don’t seem to be decreasing.

Nightingale Health Plc | Stock Exchange Release | December 12, 2025 at 2:55:00 PM EET With the expansion of the international availability of Nightingale Health Plc’s blood analysis technology for identifying disease risks and the healthcare implementation projects, the company is renewing the composition of its management team. The main focus of the new composition is on expanding the clinical use of the company’s technology globally and accelerating its commercial growth phase. The company will continue its product development investments, but the focus will shift to the growth phase of the healthcare business. The following changes will take place in the composition of the management team to implement the reform: Jeffrey Barrett, Chief Scientific Officer (CSO), who has served on Nightingale Health Plc’s management team since September 2021, will step down from his position no later than March 2026. The company will not hire a new Chief Scientific Officer but will initiate recruitment for a Chief Medical Officer (CMO). The new person’s task will be to enhance the management team’s expertise in practical clinical work and the commercial implementation of new medical methods. The company’s current management team members, Dr. Salla Ruosaari, Chief Product Development Officer, and Antti Kangas, Chief Technology Officer, one of the company’s founders, will temporarily take responsibility for leading the company’s scientific work. The company announced a change in its Chief Financial Officer on December 8, 2025. The company has started recruiting a new Chief Financial Officer. The main focus of the new person’s role is to plan and implement functions that support the company’s international commercial growth phase and to support sales growth. Following these changes, Nightingale Health Plc’s management team will focus significantly more strongly on supporting the growth phase of the healthcare business. “We are moving into the next phase of realizing our vision, and to support this, we are renewing the composition of our management team. This way, we can better achieve our ambitious goals of making better healthcare accessible to everyone. I want to thank Jeffrey for our years together and wish him success in the future,” says Teemu Suna, the company’s CEO and Founder.

Very good numbers for the new product! This is a good starting point, and that’s what TT also thought when deepening the cooperation.

One slide from Jeffrey Barrett’s UK Biobank presentation. A sample of 266 Terveystalo employees at least indicates that the test is useful for interacting with patients. There is even more dispersion in the “easy to present” section. According to Barrett, NG will launch a new version of the product in 2026, apparently with the aim of further simplifying the report.             video.silverstream.tv              UK Biobank Scientific Conference 2025

Paavola’s LinkedIn post doesn’t sound like the next steps are clear at this point:  As announced yesterday, after four great years at Nightingale Health, it is now a good time for me to move on to new challenges. During the four years, we managed to develop the finance and people functions to support the growth strategy of the company and be ready for the main market listing at Nasdaq Helsinki, which took place earlier this year. The company is now in a good place to continue its commercial growth and therefore I feel confident to hand over the baton. I want to thank all the Nightingale people and stakeholders for the amazing journey and wish you all the best! For me, after 20 years of grinding without ever taking a longer break, now it feels like a good time to take a moment to reflect about the next step at least over the holiday season. Happy to go for a lunch or have a cup of coffee to share reflections about life, the peculiarities of the universe, or why not about some future possibilities. Drop me a line  Best regards and happy holidays,  Tuukka  It’s said that he confidently passed the baton, but to my ear, it still sounds more like the initiative came from the company’s side. Interestingly, the previous CFO left after an 11-month tenure, a month before the listing. I understand that the task might specifically be to prepare the company for it, but it still feels strange that the process wouldn’t have been seen through to the end.

Not much can be said in its brief statement. Everything else would be pure speculation. And we seem to have plenty of that.

Nightingale Health

Nightingale’s growth journey has clearer guidelines thanks to revised strategy. Although the coming year will not yet be a turning point business wise for the company, the Terveystalo customer reference that is being built and new international reference that are sought still have conditions to generate evidence of successful commercial use of the company’s technology.

<p>Nightingale’s growth journey has clearer guidelines thanks to revised strategy. Although the coming year will not yet be a turning point business wise for the company, the Terveystalo customer reference that is being built and new international reference that are sought still have conditions to generate evidence of successful commercial use of the company’s technology. The visibility of success still remains weak and we stay on the sidelines waiting for the risk/return ratio to strengthen.</p> 

	2023	24e	25e
Revenue	4.2	5.0	8.5
growth-%	80.8 %	19.6 %	69.0 %
EBIT (adj.)	-18.5	-20.0	-18.7
EBIT-% (adj.)	-442.9 %	-399.7 %	-220.8 %
EPS (adj.)	-0.30	-0.32	-0.29
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	0.8	neg.	neg.

Nightingale Health: Market opening will soon be tested

Key Estimate Figures29.09.2023

Forum discussions